ClinicalTrials.gov
public full text
Public Domain
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
The purpose of this study is to determine if sorafenib (sorafenib tosylate) is a safe and effective treatment option for preventing liver cancer in high risk patients following liver transplantation. Liver transplantation is a treatment option for liver cancer patients, but despite transplantation, the liver cancer can recur in the new, transplanted liver. It is not known whether sorafenib is effective in preventing cancer recurrence in high risk patients following liver transplantation
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Relenvatinib in the Tatment of Recurrence of Hepatocellular Carcinoma After Liver Transplantation#863089
- Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer#1047908
- Combined Treatment of Treated Bile Duct Cancer#879013
- Adjuvant Lenvatinib Prevents Recurrence of High-risk Patients With HBV-related HCC After Liver Transplantation#900882
- Evaluation of AKR1B10 as a New Marker for Interventional Therapy of Hepatocellular Carcinoma#1171712
Record · ID 1060316
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive